Subtotal : 0.00Ks
Virozen S
Add to Wishlist1. Composition
Each film-coated tablet conta......
1. Composition
Each film-coated tablet contains
Lamivudine USP 150mg
Nevirapine USP 200mg
Stavudine BP 30mg
2. Indications
VIROZEN-S is indicated for the treatment of HIV infection, once patients have been stabilized on the maintenance regimen of nevirapine 200mg bd, and have demonstrated adequate tolerability to nevirapine.
3. Contraindications
VIROZEN-S is contraindicated in patients with clinically significant hypersensitivity to any of the components contained in the formulation.
VIROZEN-S is also contraindicated for patients who are just initiating therapy with nevirapine. These patients require a lead-in dose of nevirapine 200 mg o.d., whereas this formulation contains the maintenance dose of nevirapine 200 mg b.d. (see Indications).
4. Side Effects:Lamivudine Pancreatitis, Lactic acidosis and hepatic steatosis, hepatits and liver failure diarrhea, malaise and fatigue, headache, nausea and vomiting, abdominal pain and discomfort, peripheral neuropathy, arthralgias, myalgias, skin rash, pruritus, transient neutropenia and thrombocytopenia and rarely, pancreatitis.
Stavudineperipheral neuropathy, Lactic acidosis and hepatitis steatosis, hepatitis and liver failure Rash, diarrhoea, nausea/vomiting, pancreatitis, dementia and other peripheral neurologic symptoms have also been associated with the use of stavudine.Nevirapinerash and increases in liver function tests, hypersensitivity reactions mild to moderate, maculopapular erythematous cutaneous eruptions
5. Dosage and Administration
Adults
VIROZEN-S 1 tablet twice daily for patients weighing < 60 kg
VIROZEN-S should not be administered to patients who have just initiated therapy with nevirapine. This is because an initial lead-in dosing of 200 mg nevirapine once daily for 2 weeks is recommended. Following this lead-in dose, a dose escalation (maintenance dose) to 200mg nevirapinebd may be carried out in the absence of any hypersensitivity reactions (e.g. rash, liver function test abnormalities; see Warnings and Precautions).
Dosage Adjustment: Because it is a fixed-dose combination, VIROZEN-S should not be prescribed for patients requiring dosage adjustment, such as those with low body weight (<50 kg).
Patients who interrupt nevirapine dosing for more than 7 days should restart the recommended dosing, using one 200 mg Nevimune tablet daily for the first 14 days (lead-in) in combination with the other antiretrovirals, followed by 200mg twice daily using VIROZEN-S in the absence of any signs of hypersensitivity. No data are available to recommend a dosage of nevirapine in patients with hepatic dysfunction, renal insufficiency or undergoing dialysis.
This medicine is Prescription Only Medicine (POM ) and required under medical supervision.
ဤဆေးသည် POM ဆေးအုပ်စုတွင်ပါဝင်သောကြောင့် ဆရာဝန်ညွှန်ကြားချက်အတိုင်းသာ သုံးစွဲသင့်ပါသည်။
Size : 6 x 10’s = 60 tablets
Description
Virozen S
1. Composition
Each film-coated tablet contains
Lamivudine USP 150mg
Nevirapine USP 200mg
Stavudine BP 30mg
2. Indications
VIROZEN-S is indicated for the treatment of HIV infection, once patients have been stabilized on the maintenance regimen of nevirapine 200mg bd, and have demonstrated adequate tolerability to nevirapine.
3. Contraindications
VIROZEN-S is contraindicated in patients with clinically significant hypersensitivity to any of the components contained in the formulation.
VIROZEN-S is also contraindicated for patients who are just initiating therapy with nevirapine. These patients require a lead-in dose of nevirapine 200 mg o.d., whereas this formulation contains the maintenance dose of nevirapine 200 mg b.d. (see Indications).
4. Side Effects:Lamivudine Pancreatitis, Lactic acidosis and hepatic steatosis, hepatits and liver failure diarrhea, malaise and fatigue, headache, nausea and vomiting, abdominal pain and discomfort, peripheral neuropathy, arthralgias, myalgias, skin rash, pruritus, transient neutropenia and thrombocytopenia and rarely, pancreatitis.
Stavudineperipheral neuropathy, Lactic acidosis and hepatitis steatosis, hepatitis and liver failure Rash, diarrhoea, nausea/vomiting, pancreatitis, dementia and other peripheral neurologic symptoms have also been associated with the use of stavudine.Nevirapinerash and increases in liver function tests, hypersensitivity reactions mild to moderate, maculopapular erythematous cutaneous eruptions
5. Dosage and Administration
Adults
VIROZEN-S 1 tablet twice daily for patients weighing < 60 kg
VIROZEN-S should not be administered to patients who have just initiated therapy with nevirapine. This is because an initial lead-in dosing of 200 mg nevirapine once daily for 2 weeks is recommended. Following this lead-in dose, a dose escalation (maintenance dose) to 200mg nevirapinebd may be carried out in the absence of any hypersensitivity reactions (e.g. rash, liver function test abnormalities; see Warnings and Precautions).
Dosage Adjustment: Because it is a fixed-dose combination, VIROZEN-S should not be prescribed for patients requiring dosage adjustment, such as those with low body weight (<50 kg).
Patients who interrupt nevirapine dosing for more than 7 days should restart the recommended dosing, using one 200 mg Nevimune tablet daily for the first 14 days (lead-in) in combination with the other antiretrovirals, followed by 200mg twice daily using VIROZEN-S in the absence of any signs of hypersensitivity. No data are available to recommend a dosage of nevirapine in patients with hepatic dysfunction, renal insufficiency or undergoing dialysis.
This medicine is Prescription Only Medicine (POM ) and required under medical supervision.
ဤဆေးသည် POM ဆေးအုပ်စုတွင်ပါဝင်သောကြောင့် ဆရာဝန်ညွှန်ကြားချက်အတိုင်းသာ သုံးစွဲသင့်ပါသည်။
Add a review